Oncotarget

Meta-Analysis:

Prognostic value of long non-coding RNA PVT1 as a novel biomarker in various cancers: a meta-analysis

Shikai Zhu, Ping Shuai, Chong Yang, Yun Zhang, Shan Zhong, Xingchao Liu, Kai Chen, Qin Ran, Hongji Yang and Yu Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:113174-113184. https://doi.org/10.18632/oncotarget.22830

Metrics: PDF 1024 views  |   HTML 1529 views  |   ?  


Abstract

Shikai Zhu1,3, Ping Shuai2,3, Chong Yang1, Yun Zhang1, Shan Zhong1, Xingchao Liu1, Kai Chen1, Qin Ran1, Hongji Yang1,3 and Yu Zhou2,3

1Organ Transplant Center, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan, P.R.China

2Sichuan Provincial Key Laboratory for Human Disease Gene Study and Institute of Laboratory Medicine, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan, P.R.China

3School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, P.R.China

Correspondence to:

Yu Zhou, email: zhouyu422@yahoo.com

Keywords: long non-coding RNA; PVT1; cancer; prognosis; lymph node metastasis

Received: August 26, 2016     Accepted: October 02, 2017     Published: December 01, 2017

ABSTRACT

Background: Plasmacytoma variant translocation 1 (PVT1) has recently been reported to be aberrantly expressed and serves as a prognostic biomarker in many types of cancers. However, its prognostic significance remains controversial. Here, we conducted a meta-analysis to investigate the prognostic value of PVT1 expression in cancers.

Results: A total of 2109 patients from 20 studies were included. The results showed that elevated PVT1 expression predicted a poor outcome for overall survival (OS) in nine types of cancers (HR = 1.40, 95% CI: 1.21–1.59). Subgroup analysis indicated that there was a significant association between PVT1 overexpression and poor OS of patients with gastric cancer, gynecology cancer and lung cancer. Furthermore, we also found a negative significant relationship between PVT1 expression and disease-free survival (HR = 1.83, 95% CI: 1.39–2.27), progression-free survival (HR = 1.63, 95% CI: 1.34–1.93) and recurrence-free survival (HR = 1.74, 95% CI: 1.01–2.47). In addition, the level of PVT1 expression was positively related to tumor size, TNM stage, lymph node metastasis and distant metastases.

Materials and Methods: A systematic search was performed through the PubMed, EMBASE, Web of Science, Ovid and Cochrane library databases for eligible studies on prognostic value of PVT1 in cancers from inception up to June, 2017. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the association between PVT1 expression and clinical outcomes.

Conclusions: PVT1 expression positively related to tumor size, TNM stages, lymph node metastasis and distant metastases, and served as a prognostic biomarker in different types of cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22830